Most analysts raise target prices on Sun Pharma after strong Q2

CLSA, which raised the target price on Sun Pharma the most, said the drug maker's results were above estimates with key geographies performing well. Sun Pharma shares ended down 3.3% at ₹788 on Wednesday.

from Markets-Economic Times https://ift.tt/3bDae4D